TYK2 and psoriasis: Deucravacitinib has become the first Tyk2 inhibitor approved for moderate to severe psoriasis treatment [73], but potential indications in other IMIDs are multiple and the therapeutic potential of Tyk2 inhibitors are not limited to psoriatic disease.